Driven by the rapid increase of biologic therapies in development, advanced techniques in quantitative analysis of protein therapeutics and biomarkers by LC-MS now allow unprecedented levels of sensitivity, selectivity, precision, and accuracy. Two such approaches are high resolution accurate mass spectrometry (HRMS) and hybrid immunoaffinity liquid chromatography-mass spectrometry (IA-LC-MS).

Q² Solutions is a pioneer in helping drive advances in the bioanalysis of protein-based drugs and biomarkers. Download this insight brief to learn how we continue to incorporate advanced techniques and technologies, such as HRMS, IA-LC-MS, and low-flow chromatography and ionization, into our methodologies to optimize our customers' drug development outcomes.

Author:
Barry Jones, Ph.D., Associate Director, LCMS Biologics and Biomarkers

Complete the form below to access this insight brief